170 related articles for article (PubMed ID: 18757400)
21. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
[TBL] [Abstract][Full Text] [Related]
22. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
23. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.
Nieborowska-Skorska M; Stoklosa T; Datta M; Czechowska A; Rink L; Slupianek A; Koptyra M; Seferynska I; Krszyna K; Blasiak J; Skorski T
Cell Cycle; 2006 May; 5(9):994-1000. PubMed ID: 16687921
[TBL] [Abstract][Full Text] [Related]
24. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
25. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A; Bumm TG; Corbin AS; O'Hare T; Loriaux M; VanDyke J; Willis SG; Deininger J; Nakayama KI; Druker BJ; Deininger MW
Blood; 2008 Sep; 112(5):1960-70. PubMed ID: 18559973
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Deutsch E; Dugray A; AbdulKarim B; Marangoni E; Maggiorella L; Vaganay S; M'Kacher R; Rasy SD; Eschwege F; Vainchenker W; Turhan AG; Bourhis J
Blood; 2001 Apr; 97(7):2084-90. PubMed ID: 11264175
[TBL] [Abstract][Full Text] [Related]
27. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
[TBL] [Abstract][Full Text] [Related]
28. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
29. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
30. Constitutive 53BP1/γH2AX foci are increased in cells of ALL patients dependent on BCR-ABL and TEL-AML1 preleukemic gene fusions.
Somsedikova A; Markova E; Kolenova A; Puskacova J; Kubes M; Belyaev I
Neoplasma; 2014; 61(5):617-25. PubMed ID: 25244981
[TBL] [Abstract][Full Text] [Related]
31. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
32. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
33. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
35. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
36. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
38. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
39. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
40. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
